Forward Looking Statements This presentation contains, in addition to historical information, statements that look forward in time or that express management s beliefs, expectations or hopes. Such statements are forward

Ongoing discussions with large pharmaceutical companies to provide foundation for partnering opportunities at the most opportune time 2013 Galectin Therapeutics NASDAQ:GALT 35 Proprietary Compounds First in class, proprietary compounds that inhibit galectin proteins Complex carbohydrate drugs with favorable safety profile GR MD 02: Potential to treat non alcoholic steatohepatitis (NASH) and other causes of liver fibrosis GM CT 01: Potential to enhance cancer immunotherapy Validated Science Pre clinical models show galectins are critical targets for intended diseases with mechanisms that would be novel in the market Large Market Opportunities NASH and liver fibrosis indications would be first therapies for completely unmet medical needs, representing a multi billion dollar market Enhancing the ability of immune system to kill cancer cells is synergistic with many current and experimental therapies Intellectual Property Strong patent position Sole ownership of compounds in development No licenses granted Experienced Management Team Management team has significant collective experience in multiple biotech and pharmaceutical companies and relevant scientific areas 36 Investment Highlights 2013 Galectin Therapeutics NASDAQ:GALT APPENDIX 2013 Galectin Therapeutics NASDAQ:GALT 37 Inhibition of Gal 3 May Have Multiple Sites of Action in Therapy of NASH Stellate Cells Macrophages Inhibit scavenger receptor mechanism and reduce cellular toxicity Potential sites of anti galectin activity Reduces activation of stellate cells.

Chiles Research Institute (EACRI) : Ongoing pre clinical studies; phase 1 clinical trial in melanoma with combination of Yervoy and GR MD 02 in design phase Ongoing discussions with large pharmaceutical companies in the immunotherapy space to seek a partnering opportunity to take beyond proof of concept from initial clinical trials 32 2013 Galectin Therapeutics NASDAQ:GALT Agenda The Company and Key Team Members Galectins and Disease Fibrosis Program our key focus Tumor Immunotherapies Summary 2013 Galectin Therapeutics NASDAQ:GALT 33 Finances September 20, 2013 cash balance: $9.8 million Raised $6 million from private placement and warrant exercises in July/August 2013 Funded through Q2 2014 and completion of Phase I clinical trial for GR MD 02 Additional funding required for a Phase 2 clinical trial for GR MD 02 Ongoing discussions with potential partners Actively supporting Investor Relations: Talking to new and interested fundamental investors; growing interest in funding Phase 2 program Fundamental investors are value investors with 3 5 year time horizon who are interested in investing at market 2013 Galectin Therapeutics NASDAQ:GALT 34 Development Program Liver Fibrosis First indication: GR MD 02 in NASH with advanced fibrosis Phase 1 clinical trial underway; interim data Jan. 2014 Other Organ Fibrosis: Studies to demonstrate broad application of drugs in organ fibrosis; seek partner Cancer Therapy: Combination immunotherapy to enhance the ability of the immune system to recognize and kill tumor cells in metastatic melanoma Leverage world class expertise in basic tumor immunology and in the conduct of melanoma clinical trials.

Linch, Melissa J. Kasiewicz, Peter G. Traber, and William L. Redmond Cancer Therapy Strategy: Summary Two immunotherapy agents have been approved for use to date, with many more vaccines and activators in development Our strategy is to leverage world class expertise in basic tumor immunology and in the conduct of melanoma clinical trials. Ludwig Cancer Institute: Complete ongoing clinical trial with interim results reported at appropriate intervals Earle A.

Chiles Research Institute (EACRI) to evaluate the effect of galectin inhibitors on the induction of T cell activity alone and in combination with checkpoint inhibitor blockade. Checkpoint inhibitor blockage plus GR MD 02 boosts anti tumor immunity in syngeneic mouse models of prostate and breast cancer 2013 Galectin Therapeutics NASDAQ:GALT 31 *p 0.05 aCTLA 4 = anti CTLA 4 mAb [ipilimumab in humans (Yervoy, BMS)] aPD 1 = anti PD 1 mAb [positive results in clinical trials, BMS, Merck] Unpublished data 2013: Stefanie N.

Potential for galectin inhibitors to enhance anti tumor immune response 2. Potential for galectin inhibitors to enhance anti tumor activity of T cells by blocking Galectin Effect Ludwig Institute Clinical Trial to Evaluate combination of melanoma vaccine with GM CT 01 28 Melanoma Proof of Concept Trial: Patients: Metastatic melanoma Design: Two stage Phase 2a (6x2 cohorts in stage 1 and 23x2 cohorts in stage 2) Regimen: Prime with melanoma specific peptide vaccine (overall 60% of melanoma patients express one or the other antigens) then treat with GM CT 01 Endpoint: Partial or complete response by imaging Study sites: Ludwig Institute, Brussels Belgium; second site Antwerp Study funding: Ludwig Institute (stage 1; 12 patients) Group 2 patients have additional injection of GM CT 01 in cutaneous tumors 2013 Galectin Therapeutics NASDAQ:GALT Clinical Trial LUC10 001: Accrual 2013 Galectin Therapeutics NASDAQ:GALT 29 No grade 3/4 adverse events or serious adverse events Two out of three mixed responses encouraging, but no responses by RECIST Patient accrual continuing Note: one center at initiation and first patient completed protocol before more enrolled; once safety confirmed additional patients enrolled and second center initiated 30 Potential sites for galectin inhibition in tumor immunotherapy 2013 Galectin Therapeutics NASDAQ:GALT Collaboration established in 2012 with Earle A.

Franz Cancer Research Center, Earle A. Chiles Research Institute (EACRI) Providence Portland Medical Center, Portland Oregon 2013 Galectin Therapeutics NASDAQ:GALT 26 27 Potential sites for galectin inhibition in tumor immunology 2013 Galectin Therapeutics NASDAQ:GALT Immunotherapies Checkpoint Inhibitor Blockade: anti CTLA4 anti PD1 Tumor Vaccines 1.

Competition in NASH Most drugs in development focus on improving NASH activity score (fat, inflammation, and cell death) with minimal amounts of fibrosis. Few companies are focused on fibrosis which is the key cause of liver failure in patients Galectin: GR MD 02 Gilead: Lysyl oxidase like 2 mAb (GS 6624): Monoclonal antibody that blocks the enzyme which cross links collagen fibers Initiated Phase 2 trials in 2012 in patients with NASH and fibrosis Top line data Q3 2015 2013 Galectin Therapeutics NASDAQ:GALT 21 Fibrosis Strategy Summary NASH with Advanced Fibrosis: Evidence of efficacy of GR MD 02 from well controlled phase 2 clinical trial Other Organ Fibrosis: Potential for partnering opportunities Lung fibrosis pre clinical results suggest possible use in Idiopathic Pulmonary Fibrosis Kidney fibrosis Ongoing discussions with large pharmaceutical companies Discussions will provide foundation for partnering opportunities at the most opportune time 2013 Galectin Therapeutics NASDAQ:GALT 22 Agenda The Company and Key Team Members Galectin Inhibitors Fibrosis Program our key focus Tumor Immunotherapies Summary 2013 Galectin Therapeutics NASDAQ:GALT 23 2013 Galectin Therapeutics NASDAQ:GALT 24 Marketed: CTLA4 receptor mAb: Yervoy (Ipilimumab, BMS) In Development: Anti PD 1 (nivolumab BMS; lambrolizumab Merck) Anti PD L1 (MPDL3280A , Roche) May 22, 2010 Checkpoint Inhibitor Blockade The Vast Majority of Cancers Secrete Large Amounts of Galectins Which Have Multiple Roles in Tumor Pathogenesis Tumor cell invasion: extracellular matrix adhesion detachment Metastasis: cell invasion and migration Angiogenesis Tumor immunity has recently been shown to be critically affected by galectins 25 2013 Galectin Therapeutics NASDAQ:GALT Cancer Therapy Strategy Focus on tumor immunotherapy Hypothesis: galectin inhibitors will enhance efficacy of immunotherapies Metastatic melanoma is initial cancer indication We have sought collaborations with institutions that have: Demonstrated clinical trial expertise in melanoma Tumor immunology basic science research Ability to conduct clinical trials and assist in funding Two collaborations have been established Ludwig Cancer Institute, Brussels Belgium Robert W.

Dose: One or two dosage groups chosen based on data from Phase 1 trial Treatment Duration: 6 12 months, TBD Primary endpoint : Liver biopsy: Collagen proportional area FDA AASLD liver fibrosis endpoints workshop, September 2013 Galectin human NASH biopsy study ongoing Secondary endpoints: Liver Biopsy: NASH Activity Score and Fibrosis Stage Imaging methods MR fat, MR elastography Serum biomarkers based on analysis of Phase 1 data Estimated Timeline: Start 2H 2014; Top line data: 1H 2016.

Single IV dose followed by three additional weekly doses in each cohort. At least three dose escalation cohorts guided by PK. Option to add additional cohorts. Dose: Starting dose of 2 mg/kg which is within the presumptive therapeutic range Primary endpoints: Patient safety Pharmacokinetics Secondary endpoints: Exploratory serum biomarkers to assess for potential treatment effect including markers for inflammation, cell death, and fibrogenesis Cohort 2 Cohort 3 Guided by exposure from previous cohort 20 Phase 2 Clinical Trial Plans 2013 Galectin Therapeutics NASDAQ:GALT Patient inclusion : Biopsy proven NASH with advanced fibrosis (stage 3 and potentially stage 4 with well compensated cirrhosis) Design : Randomized, placebo controlled, and double blind.

GR MD 02 more effective than GM CT 01 GMP drug substance and product produced by CMO Studies completed in multiple species elucidating pharmacology, pharmacokinetics, and toxicology. FDA review of IND for GR MD 02 submitted Jan. 30, 2013 resulted in approval for human clinical studies. Phase 1 trial underway enrolling first cohort FDA Fast Track designation received August 2013 2013 Galectin Therapeutics NASDAQ:GALT 17 Development Program: Targeting Therapy In The Progression of NASH 18 Development of Obesity Insulin Resistance/Diabetes Steatosis (fatty liver) NASH Fibrosis Cirrhosis Decades Because of effect on inflammation in NASH and ability to reduce existing fibrosis, our clinical program will target NASH patients with advanced fibrosis 2013 Galectin Therapeutics NASDAQ:GALT 19 M J J A S O N D J F M A M J 2013 2014 Cohort 1 Phase 1 Clinical Trial 2013 Galectin Therapeutics NASDAQ:GALT Sites: Top academic investigators in NASH; all US sites Patient inclusion: Biopsy proven NASH with advanced fibrosis (stage 3) Design: Dose escalation combining single and multiple dose in design.

Prevalence of NASH in U.S. is between 9 15 million people Over 25% will develop cirrhosis NASH cirrhosis projected to be primary reason for liver transplant 2013 Galectin Therapeutics NASDAQ:GALT 16 NASH with Fibrosis Development Program: Accomplishments NASH indication chosen based on pre clinical experiments Multiple studies in animal models confirmed robust effect on inhibition and regression of fibrosis, as well as reduction in inflammation and cell death in the liver.

Lung fibrosis induced by tracheal instillation of bleomycin followed by four infusions of either vehicle or GR MD 02 Potential Use in Kidney Fibrosis: GR MD 02 Reduces Fibrosis in Diabetic Mouse 2013 Galectin Therapeutics NASDAQ:GALT 15 Vehicle Normal GR MD 02 Reduction in interstitial fibrosis Arrows show areas of interstitial fibrosis Liver Fibrosis Development Program NASH (Non Alcoholic SteatoHepatitis) Multiple liver diseases lead to fibrosis End stage fibrosis, or cirrhosis, leads to liver failure, medical complications, and death Only current therapy is liver transplant There is no approved medical therapy for liver fibrosis Very large unmet medical need First indication is fatty liver disease with fibrosis (non alcoholic steatohepatitis, or NASH).

The majority of cancers express high levels of galectin 3 Our proprietary drugs are complex carbohydrates with galactose residues that bind galectin proteins (galectin 3 galectin 1) Galactomannan (GM) class: GM CT 01 Galacto rhamnogalaturonate (GR) class: GR MD 02 Discovery pipeline Derivatives of GM and GR for subcutaneous administration Synthetic carbohydrates Small organic molecule galectin inhibitors 2013 Galectin Therapeutics NASDAQ:GALT 8 Intellectual Property GM CT Class (current NCE is GM CT 01) US Composition of matter patent issued 2011 (expires 2023) Five US issued method of use patents in combination with cancer therapy for increased efficacy and reduced side effects International Patents: 14 granted and 5 pending Method of use in liver fibrosis issued 2012 (expires 2026) Method of use in NASH patent pending (priority 2011) Method of use for Immune Enhancement pending (priority 2011) GR MD Class (current NCE is GR MD 02) Method of use in liver fibrosis patent issued (expires 2026) Method of use in NASH patent issued (expires 2031) Composition of matter patent pending (priority 2011) Method of use for Immune Enhancement pending (priority 2011) 9 2013 Galectin Therapeutics NASDAQ:GALT Sole ownership of compounds in development Agenda The Company and Key Team Members Galectins and Disease Fibrosis Program our key focus Tumor Immunotherapies Summary 2013 Galectin Therapeutics NASDAQ:GALT 10 Galectin 3 is critically important in the development of organ fibrosis Galectin 3 null mice (no galectin 3) are resistant to fibrosis due to toxin induced liver toxicity Galectin 3 null mice are also resistant to fibrosis in: Fatty liver disease Kidney fibrotic disease Lung fibrotic disease 2013 Galectin Therapeutics NASDAQ:GALT 11 Normal mouse No gal 3 mouse Red stain is collagen, the principal component of fibrotic tissue Henderson, et al 2006 Mice treated with liver toxin to induce fibrosis Normal mice develop fibrosis whereas those without gal 3 do not Galectin Inhibitors Reverse Cirrhosis in Rat 2013 Galectin Therapeutics NASDAQ:GALT 12 GR MD 02 Vehicle GM CT 01 Animal model presented a very high hurdle for drug treatment: Cirrhosis induced with high dose toxin and continued throughout drug treatment Treatment with four weekly doses Broad bands of collagen with nodule formation (N) indicates advanced fibrosis and cirrhosis Reduction in collagen with thin and broken bands (arrow) indicates resolving fibrosis and cirrhosis Galectin Inhibitor GR MD 02 Improved Fat, Liver Cell Death, Inflammation, and Fibrosis in Mouse Model of Fatty Liver Disease with Fibrosis GR MD 02 2013 Galectin Therapeutics NASDAQ:GALT 13 Control Control GR MD 02 GR MD 02 Fat Cell death Inflammation Fat Cell death Inflammation Red = Collagen Red = Collagen Potential Use in Lung Fibrosis: GR MD 02 Reduces Fibrosis in Mouse Model 2013 Galectin Therapeutics NASDAQ:GALT 14 Vehicle Normal GR MD 02 Marked reduction in area and severity of fibrosis without aggregation into larger formations Large areas of confluent fibrosis.

Galectins bind via their CRD to oligosaccharides containing terminal galactose residues on macromolecules such as glycoproteins. Function through binding glycoproteins on cell surface and extracellular space to modulate cellular and immune system function. Galectin 3 is widely expressed in mesenchymal and epithelial cells Under normal physiological situations, galectin 3 is expressed at low levels In areas of acute or chronic inflammation and fibrogenesis, the gal 3 expression is markedly increased.

GM CT 01 in Phase 2a clinical trial in combination with peptide vaccine for advanced melanoma 2013 Galectin Therapeutics NASDAQ:GALT 4 Key Facts September 20, 2013 5 2013 Galectin Therapeutics NASDAQ:GALT Trading Symbol Nasdaq: GALT Corporate Headquarters Norcross, GA (suburb of Atlanta) Stock Price; 52 Week Range $9.34 $1.60 $13.21 Shares Outstanding 17.6 million Daily Volume (50 day average) 197,930 shares Market Capitalization $164.4 million Debt $0 Cash Equivalents $9.8 million Estimated Cash Runway Funded through Q2 2014 Fiscal Year Ends December 31 Accounting Firm McGladrey LLP Experienced Leadership Team 6 2013 Galectin Therapeutics NASDAQ:GALT Agenda The Company and Key Team Members Galectin Inhibitors Fibrosis Program our key focus Tumor Immunotherapies Summary 2013 Galectin Therapeutics NASDAQ:GALT 7 Galectins Inhibitors Galectin family (15 members) are classified by structure and the number of carbohydrate binding domains (CRD).

You should not place undue reliance on forward looking statements. Although subsequent events may cause our views to change, we disclaim any obligation to update forward looking statements. 2 2013 Galectin Therapeutics NASDAQ:GALT Agenda The Company and Key Team Members Galectin Inhibitors Fibrosis Program our key focus Tumor Immunotherapies Summary 2013 Galectin Therapeutics NASDAQ:GALT 3 What We Do Clinical stage biopharmaceutical company targeting fibrotic diseases and cancer with novel compounds that inhibit galectin proteins Galectin proteins are important in the development and promotion of many fibrotic and neoplastic diseases Currently in clinical trials with 2 compounds GR MD 02 for the indication of NASH (Fatty Liver Disease) with advanced liver fibrosis: Phase 1 GM CT 01 and GR MD 02 in targeting cancer, enhance ability of immune system to kill cancer cells.

To date, we have incurred operating losses since our inception, and our ability to successfully develop and market drugs may be impacted by our ability to manage costs and finance our continuing operations. For a discussion of additional factors impacting our business, see our most recent Annual Report on Form 10 K and our subsequent filings with the SEC.

Our ongoing discussions with other companies may not lead to partnering opportunities, and if we are unable to partner with other companies and/or raise additional capital, we will likely be unable to complete future stages of clinical trials and ultimately produce revenue from our drugs in development. Funding from potential sources of capital, including the potential exercise of warrants, may not materialize.

Plans regarding development, approval and marketing of any of our drugs are subject to change at any time based on the changing needs of our company as determined by management and regulatory agencies. Estimates regarding the potential benefits of our drugs and the potential market for any of our drugs may be inaccurate and, to the extent the estimates are correct, we may not be successful in achieving revenues from any such drugs, as the successful marketing of any approved drugs will be subject to strong competition within the health care industry and patient and physician acceptance of our drugs as safe, affordable and effective.

We may have difficulty in enrolling candidates for testing and we may not be able to achieve the desired results. Upon receipt of regulatory approval for any drug or treatment, we may face competition with other drugs and treatments that are currently approved or those that are currently in development, which could have an adverse impact on our ability to achieve revenues from the approved indication.

The risks and uncertainties impacting these statements include that our plans, expectations and goals regarding drugs in development, clinical trials and regulatory approval are subject to factors beyond our control. Our clinical trials may not begin or produce positive results in a timely fashion, if at all, and any necessary changes during the course of such trials could prove time consuming and costly.

These statements relate to future events or future financial performance, and use words such as may, estimate, could, expect and others. They are based on our current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the statements. These statements include our plans, expectations and goals regarding drugs in development, clinical trials and regulatory approval for any of our drugs or treatments, the anticipated timeline for clinical trials and results, related market opportunities for our drugs, potential benefits of our drugs, efforts related to partnering opportunities with other companies, estimates regarding cash, liquidity and funding requirements for clinical trials, and estimates regarding those impacted by NASH, liver fibrosis and cirrhosis.

Corporate Presentation September 2013 NASDAQ: GALT www.galectintherapeutics.com Exhibit 99.1 Forward Looking Statements This presentation contains, in addition to historical information, statements that look forward in time or that express management s beliefs, expectations or hopes. Such statements are forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

TGF receptor activity ECM dissolution by macrophage action 2013 Galectin Therapeutics NASDAQ:GALT Reduce Gal 3 activation and/or shift polarity of macrophages 38 CONFIDENTIAL